On March 6, 2026, Celularity Inc. entered an agreement to sell its biomaterials portfolio and grant licenses to NexGel, Inc. for up to $35 million, including a $15 million upfront payment and $20 million in potential milestone payments. The transaction is subject to customary terms, including financing conditions for the upfront payment.